4.7 Article

AACR Project GENIE: Powering Precision Medicine through an International Consortium

Journal

CANCER DISCOVERY
Volume 7, Issue 8, Pages 818-831

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-17-0151

Keywords

-

Categories

Funding

  1. Howard Hughes Medical Institute
  2. NCI [CA008748, CA016672]
  3. Princess Margaret Cancer Foundation
  4. Cancer Core Ontario Applied Clinical Research Unit
  5. University of Toronto Division of Medical Oncology Strategic Innovation
  6. Ontario Ministry of Health & Long Term Care Academic Health Services Centre
  7. Funding Plan Innovation Award (University Health Network)
  8. Susan G. Komen [SAC110052]
  9. NIH [5U01CA168394, 5P50CA098258, 5P50CA083639, U54HG008100, U24CA210950, U24CA209851]
  10. Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  11. CCSG [CA016672, 5P30CA068485-21]
  12. CPRIT Precision Oncology Decision Support Core Grant (University of Texas MD Anderson Cancer Center) [RP150535]
  13. NCI core grant [2P30CA006516-52, CA006973]
  14. T.J.Maryland Cigarette Restitution Fund Research Grant Martell Foundation
  15. Commonwealth Foundation [CA121113, CA180950]
  16. Pfizer
  17. Eli Lilly
  18. Dutch Ministry of Health (Dutch National Cancer Institute)
  19. Dutch Cancer Society
  20. Pilot Infrastructure Initiative Project [8166]
  21. Translational Research IT (TraIT) in transition to Health-RI, sustaining support for translational cancer research

Ask authors/readers for more resources

The AACR Project GENIE is an international data-sharing consortium focused on generating an evidence base for precision cancer medicine by integrating clinicalgrade cancer genomic data with clinical outcome data for tens of thousands of cancer patients treated at multiple institutions worldwide. In conjunction with the first public data release from approximately 19,000 samples, we describe the goals, structure, and data standards of the consortium and report conclusions from high-level analysis of the initial phase of genomic data. We also provide examples of the clinical utility of GENIE data, such as an estimate of clinical actionability across multiple cancer types (> 30%) and prediction of accrual rates to the NCI-MATCH trial that accurately reflect recently reported actual match rates. The GENIE database is expected to grow to > 100,000 samples within 5 years and should serve as a powerful tool for precision cancer medicine. SIGNIFICANCE: The AACR Project GENIE aims to catalyze sharing of integrated genomic and clinical datasets across multiple institutions worldwide, and thereby enable precision cancer medicine research, including the identification of novel therapeutic targets, design of biomarker-driven clinical trials, and identification of genomic determinants of response to therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available